INSM vs AMGN vs ALNY Stock Comparison

Insmed, Amgen and Alnylam Pharmaceuticals Prices as of Nov 13, 2026 Peers: Industry group
INSM INSMED Inc
$121.16 +23.9% 1M -36.6% 1Y
Market cap
$26.90B
P/E
–
Revenue (TTM)
$1.52B
Div. yield
–
Biotechnology Healthcare
2 wins
AMGN Amgen Inc
$465.67 +9.3% 1M +38.6% 1Y
Market cap
$250.23B
P/E
26.6x
Revenue (TTM)
$38.90B
Div. yield
0.02%
Biotechnology Healthcare
4 wins

Head to Head

11 decided of 12

Alnylam Pharmaceuticals leads on 5 of the 12 questions below (Alnylam Pharmaceuticals 5, Amgen 4, Insmed 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionINSMAMGNALNYLeader
Larger companyMarket capitalisation $26.90B $250.23B $21.33B AMGN
Cheaper on earningsLower P/E, profitable companies only -44.4x 26.6x 8.1x ALNY
Cheaper on forward earningsLower price / next fiscal year consensus EPS — 20.9x 8.6x ALNY
Faster revenue growthRevenue growth, trailing twelve months +240.0% +8.2% +60.8% INSM
More profitableNet margin, trailing twelve months -39.9% 24.1% 52.8% ALNY
Better return on capitalReturn on invested capital -41.1% 15.6% — AMGN
Less leveragedLower net debt / EBITDA 1.1x 2.4x -3.1x ALNY
Higher dividend yieldTrailing dividend yield 0.00% 0.02% 0.00% –
Better 1-year returnPrice return, last 12 months -36.6% +38.6% -63.6% AMGN
Better 5-year returnAnnualised price return, 5 years +30.6%/yr +17.1%/yr -0.7%/yr INSM
Less volatileAnnualised volatility, 1 year 62.2% 28.8% 59.1% AMGN
Higher overall scoreMean of the five percentile scores vs peers 66/100 66/100 81/100 ALNY

Percentile Scorecard

INSMAMGNALNY

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisINSMAMGNALNY
Valuation 70 #201 of 660 85 #103 of 660 91 #61 of 660
Growth 85 #91 of 619 61 #245 of 619 99 #10 of 619
Profitability 69 #186 of 595 95 #32 of 595 91 #55 of 595
Financial Health 37 #428 of 683 23 #528 of 683 61 #269 of 683
Shareholder Returns 67 #153 of 459 67 #152 of 459 66 #156 of 459
Overall 66 66 81
  • INSM ranked among 695 companies in Pharmaceuticals and Biotechnology
  • AMGN ranked among 695 companies in Pharmaceuticals and Biotechnology
  • ALNY ranked among 695 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodINSMAMGNALNYSPY
1 month +23.9%+9.3%-26.5% -2.0%
3 months -2.1%+12.2%-27.8% -2.8%
6 months +11.0%+42.7%-42.5% +2.0%
Year to date -30.4%+42.3%-58.5% +10.6%
1 year -36.6%+38.6%-63.6% +12.2%
3 years +393.7%+72.5%-2.9% +68.1%
3 years, per year +70.3%+19.9%-1.0% +18.9%
5 years +280.3%+120.3%-3.4% +61.4%
5 years, per year +30.6%+17.1%-0.7% +10.1%
10 years +738.5%+212.4%+254.6% +248.5%
10 years, per year +23.7%+12.1%+13.5% +13.3%

Risk

MeasureINSMAMGNALNYSPY
Volatility, 1Y 62.2%28.8%59.1% 13.6%
Downside volatility, 1Y 61.0%28.4%74.1% 13.9%
Beta vs S&P 500, 1Y 0.550.490.50 1.00
Return / volatility, 1Y -0.591.34-1.08 0.90
Max drawdown, 5Y -56.5%-26.7%-69.1% -25.4%
From 52-week high -42.7%-2.7%-65.1% -3.2%
52-week high $211.41$478.48$473.29 $779.14
52-week low $91.88$313.85$151.64 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleINSMAMGNALNY
P/E now vs peer median -43.8xmedian 17.0x 26.8xmedian 17.0x 8.3xmedian 17.0x
P/S now vs peer median 17.5xmedian 8.4x 6.5xmedian 8.4x 4.4xmedian 8.4x
EV/EBITDA now vs peer median -48.6xmedian 14.6x 17.1xmedian 14.6x 18.3xmedian 14.6x
P/FCF now vs peer median -42.3xmedian 19.0x 26.3xmedian 19.0x 27.4xmedian 19.0x
P/B now vs peer median 36.6xmedian 2.0x 17.6xmedian 2.0x 6.1xmedian 2.0x
PEG now vs peer median -2.40median 0.43 3.86median 0.43 0.09median 0.43

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsINSMAMGNALNY
Revenue $1.52B $38.90B $5.01B
Gross profit $1.28B $27.58B $3.88B
Operating income -$563.99M $12.61B $977.59M
Net income -$605.67M $9.39B $2.65B
Free cash flow -$627.58M $9.58B $806.31M
R&D $944.39M $7.84B $1.56B
EPS (diluted) $-2.77 $17.20 $19.19
Cash & equivalents $396.60M $13.19B $1.75B
Total debt $555.09M $54.01B $361.53M
Shares (diluted) 218.79M 546.00M 138.04M
Enterprise value $21.94B $201.89B $8.52B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricINSMAMGNALNY
P/E -43.8x 26.8x 8.3x
P/FCF -42.3x 26.3x 27.4x
P/Operating cash flow -44.6x 20.9x 23.1x
P/S 17.5x 6.5x 4.4x
P/B 36.6x 17.6x 6.1x
P/Tangible book 45.2x -48.6x 6.1x
EV/EBITDA -48.6x 17.1x 18.3x
EV/EBIT -46.1x 23.2x 19.3x
EV/Revenue 17.1x 7.5x 3.8x
EV/FCF -41.4x 30.5x 23.4x
EV/Operating cash flow -43.6x 24.3x 19.7x
PEG (3Y EPS CAGR) -2.40 3.86 0.09

Growth

14 metrics
MetricINSMAMGNALNY
Revenue growth (1Y) 240.0% 8.2% 60.8%
Revenue CAGR (3Y) 75.6% 13.2% 42.7%
Gross profit growth (1Y) 274.9% 15.9% 49.6%
Gross profit CAGR (3Y) 79.8% 11.8% 37.8%
Operating income growth (1Y) 51.3% 45.4% 269.3%
Operating income CAGR (3Y) 6.2% 12.5% 68.2%
Net income growth (1Y) 48.8% 34.1% 2,137%
Net income CAGR (3Y) 5.8% 7.5% 93.1%
EPS growth (1Y) 50.5% 33.1% 2,126%
EPS CAGR (3Y) 18.2% 6.9% 90.8%
Operating cash flow growth (1Y) 32.6% -8.3% 351.6%
Operating cash flow CAGR (3Y) -5.4% 4.4% 685.4%
Free cash flow growth (1Y) 30.7% -17.0% 382.3%
Free cash flow CAGR (3Y) -6.2% 0.7% 141.7%

Profitability

14 metrics
MetricINSMAMGNALNY
Gross margin 84.4% 70.9% 77.4%
EBITDA margin -35.1% 43.9% 20.6%
Operating margin -37.1% 32.4% 19.5%
Pretax margin -39.4% 28.4% 15.6%
Net margin -39.9% 24.1% 52.8%
FCF margin -41.3% 24.6% 16.1%
Operating cash flow margin -39.2% 30.9% 19.1%
Return on equity -81.9% 72.1% 106.4%
Return on assets -28.1% 9.8% 38.9%
Return on invested capital -41.1% 15.6% –
Return on capital employed -36.0% 17.4% 20.7%
Asset turnover 0.7x 0.4x 0.7x
Cash conversion (OCF / net income) 1.0x 1.3x 0.4x
Stock comp / revenue 11.0% 1.3% 6.1%

Financial Health

11 metrics
MetricINSMAMGNALNY
Debt / assets 24.9% 56.2% 4.5%
Debt / equity 0.8x 3.8x 0.1x
Net debt / EBITDA 1.1x 2.4x -3.1x
Debt / FCF -0.9x 5.6x 0.4x
Liabilities / assets 67.4% 85.1% 54.9%
Equity / assets 32.6% 14.9% 45.1%
Interest coverage -5.5x 4.8x 3.2x
Current ratio 2.9x 1.5x 2.5x
Quick ratio 2.4x 1.0x 2.3x
Cash ratio 1.9x 0.6x 1.7x
Altman Z-score 7.36 2.54 3.78

Shareholder Returns

7 metrics
MetricINSMAMGNALNY
Dividend yield – 2.1% –
Net buyback yield -0.4% – -0.5%
Shareholder yield -0.4% 2.1% -0.5%
Payout ratio (earnings) – 57.1% –
Payout ratio (FCF) – 56.0% –
Dividend growth (1Y) – 6.3% –
Dividend CAGR (3Y) – 6.4% –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusINSMAMGNALNY
Forward P/E – 20.9xFY2026 8.6xFY2026
EPS, next fiscal year $-1.68FY2026 $22.28FY2026 $19.15FY2026
EPS growth, next FY – +2.0%FY2026 +721.9%FY2026
EPS growth, the year after – +7.2% -56.0%
Revenue, next fiscal year $1.99BFY2026 $42.01BFY2026 $5.65BFY2026
Revenue growth, next FY +227.7%FY2026 +14.3%FY2026 +52.2%FY2026
Revenue growth, the year after +59.5% +3.1% +23.3%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersINSMAMGNALNY
Held by institutions 100.0% 82.7% 99.7%
Institutions holding 671 3,163 788
Change in shares held, QoQ +3.4% +4.5% +3.8%
Institutions buying 369 1,452 412
Institutions selling 230 1,219 279
Buyers to sellers 1.60 1.19 1.48

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

INSMAMGNALNY
INSM 1.00 0.15 0.02
AMGN 0.15 1.00 0.24
ALNY 0.02 0.24 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, INSM, AMGN and ALNY?

Amgen (AMGN) is the largest by market capitalisation: Insmed (INSM) $26.90B, Amgen (AMGN) $250.23B, Alnylam Pharmaceuticals (ALNY) $21.33B.

Which stock is cheaper, INSM, AMGN and ALNY?

Alnylam Pharmaceuticals (ALNY) trades on the lowest price-to-earnings ratio (Insmed (INSM) -44.4x, Amgen (AMGN) 26.6x, Alnylam Pharmaceuticals (ALNY) 8.1x). On next year's consensus earnings, Alnylam Pharmaceuticals (ALNY) is cheapest (Amgen (AMGN) 20.9x, Alnylam Pharmaceuticals (ALNY) 8.6x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Insmed (INSM) grew revenue fastest over the trailing twelve months: Insmed (INSM) +240.0%, Amgen (AMGN) +8.2%, Alnylam Pharmaceuticals (ALNY) +60.8%.

Which company is more profitable?

Alnylam Pharmaceuticals (ALNY) has the highest net margin (Insmed (INSM) -39.9%, Amgen (AMGN) 24.1%, Alnylam Pharmaceuticals (ALNY) 52.8%). On return on invested capital, Amgen (AMGN) leads (Insmed (INSM) -41.1%, Amgen (AMGN) 15.6%).

Which stock has performed better?

Over the past year Amgen (AMGN) returned the most: Insmed (INSM) -36.6%, Amgen (AMGN) +38.6%, Alnylam Pharmaceuticals (ALNY) -63.6%. Over five years, Insmed (INSM) compounded fastest (Insmed (INSM) +30.6%/yr, Amgen (AMGN) +17.1%/yr, Alnylam Pharmaceuticals (ALNY) -0.7%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Insmed (INSM) 0.00%, Amgen (AMGN) 0.02%, Alnylam Pharmaceuticals (ALNY) 0.00%. Insmed (INSM) and Alnylam Pharmaceuticals (ALNY) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Amgen (AMGN) has been the steadiest (Insmed (INSM) 62.2%, Amgen (AMGN) 28.8%, Alnylam Pharmaceuticals (ALNY) 59.1%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, INSM, AMGN and ALNY?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Alnylam Pharmaceuticals (ALNY) leads on 5. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.